Rationale and study design of CheckMate-649 biomarker analysis
CheckMate 649: 1L nivo + chemotherapy improves OS
CheckMate 649 biomarker analyses of NIVO + IPI vs chemo for patients with GC/GEJC/EAC
Checkmate 649 | Out now on Plenary Session Podcast feed
Future directions of research following the CheckMate-649 trial
Geoffrey Y. Ku, MD, offers opinion on the practice-changing potential of the CheckMate-649 study
#ESMO21 Expert Video Report on immunotherapy in gastro-oesophageal cancer
CheckMate 649, un approfondimento sul follow-up a 4 anni
Expert Video Report on immunotherapy in gastro oesophageal cancer from 2021 ASCO Annual Meeting
Overview of gastroesophageal cancer
Adding Immunotherapy to First-Line Chemotherapy for Gastric Cancer: Data and Implications
Catalysts for Change in Gastric & GEJ Cancer
しっかり知りたい胃がん治療のこと:胃がんから知るがん治療の今、そして明日
Gastrointestinal Cancer CME Series: Gastroesophageal Cancer
Upper Gastrointestinal Cancer | 2022 OneOncology Conference
Update on the CheckMate649 trial in treatment-naïve GEA
Immune checkpoint inhibitors and combination strategies for patients with gastric cancer
Beyond the Horizon in Gastric Cancer: Updated Evidence on How Systemic Therapies Are Redefining Care
Clinical Trials Updates for Gastric Cancer Patients
Personalized treatment of advanced HER2-negative gastric or gastroesophageal junction cancer